Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q86TX2

UPID:
ACOT1_HUMAN

ALTERNATIVE NAMES:
CTE-I; CTE-Ib; Inducible cytosolic acyl-coenzyme A thioester hydrolase; Long chain acyl-CoA thioester hydrolase; Palmitoyl-coenzyme A thioesterase

ALTERNATIVE UPACC:
Q86TX2; A1L173; Q3I5F9

BACKGROUND:
The enzyme Acyl-coenzyme A thioesterase 1, with aliases such as CTE-Ib and Palmitoyl-coenzyme A thioesterase, is integral to the regulation of fatty acid metabolism. It efficiently hydrolyzes saturated and unsaturated long chain fatty acyl-CoAs, maintaining the balance of free fatty acids and coenzyme A in the cell.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Acyl-coenzyme A thioesterase 1 holds the key to unlocking new therapeutic approaches. Given its critical role in managing fatty acid levels, this enzyme could be a target for treating diseases linked to lipid dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.